Incubated by Vision Institute, the retinal disease gene therapy developer has secured $52.8m in a round co-led by UPMC Enterprises.

UPMC Enterprises, the commercialisation and venture capital arm of University of Pittsburgh Medical Center, co-led a €44.5m ($52.8m) funding round for France-based ocular therapy developer SparingVision on Wednesday.
The round was co-led by investment firm 4Bio Capital and included Bpifrance, Foundation Fighting Blindness, Jeito Capital and Ysios Capital.
Incubated by research centre Vision Institute’s incubator, Incubateur Voir & Entendre, in 2016, SparingVision is working on gene therapies for blinding retinal disorders. Its lead drug candidate, SPVN06, is being…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in